Skip Navigation



Annals of Oncology Advance Access published online on October 3, 2006
Annals of Oncology, doi:10.1093/annonc/mdl288
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/11/1693    most recent
mdl288v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ng, A. K.
Right arrow Articles by Mauch, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ng, A. K.
Right arrow Articles by Mauch, P. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology
Received March 29, 2006
Revised June 26, 2006
Accepted June 30, 2006

original article

Long-term results of a prospective trial of mantle irradiation alone for early-stage Hodgkin's disease

A. K. Ng 1, S. Li 2, D. Neuberg 2, D. C. Fisher 3, C. McMillan 1, B. Silver 1, K. C. Marcus 4, M. A. Stevenson 5, and P. M. Mauch 1 *

1 Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute
2 Department of Biostatistical Sciences
3 Department of Adult Oncology, Dana-Farber Cancer Institute
4 Department of Radiation Oncology, The Children's Hospital
5 Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Boston, USA

* To whom correspondence should be addressed.
P. M. Mauch, E-mail: pmauch{at}lroc.harvard.edu


  Abstract

Background: To determine the long-term treatment outcome and late effects of mantle irradiation alone in selected patients with early-stage Hodgkin's disease.

Methods: Between 1988 and 2000, 87 patients with pathologic stage (Ann Arbor) I-IIA or clinical stage IA Hodgkin's disease were entered on to a prospective trial of mantle irradiation alone. Patients with B symptoms, large mediastinal adenopathy, or subcarinal or hilar involvement were excluded. The median doses to the mantle field and mediastinum were 36 Gy (range 30.3-40) and 38.6 Gy (range 30.6-44), respectively. The actuarial freedom from treatment failure (FFTF) and overall survival (OS) rates were calculated using the Kaplan-Meier technique.

Results: The median follow-up was 107 months (range 23-192). Thirteen of 87 patients (15%) relapsed at a median of 30 months (range 5-62). The 5- and 10-year actuarial FFTF rates were 86% and 84.7%, respectively. All 13 patients who relapsed are alive without evidence of disease at a median of 84 months (range 30-156) post-salvage therapy. Five patients developed a second malignancy at a median of 93 months (range 27-131). The 10-year actuarial risk of a second malignancy was 4.5%. There have been two deaths to date, both due to second malignancies. The 10-year OS rate was 98.2%.

Conclusion: In selected patients with early-stage Hodgkin's disease, mantle irradiation alone has an excellent long-term survival rate, comparing favorably with the previous standard treatment of extended-field radiation therapy and the current standard of combined modality therapy.

Keywords: Hodgkin's disease; radiation therapy; late effects.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.